Other BH3-mimetics with reported clinical data include the pan-BCL2 family inhibitor obatoclax, which demonstrated limited selectivity for BCL2, minimal clinical efficacy and troublesome off-target neuropsychiatric toxicities in phase I trials [17, 18] and the MCL1 inhibitor AMG-176, which achieved infrequent responses (12%) in relapsed/refractory (R/R) multiple myeloma [19]. The gene discussed is MCL1; the disease is plasma cell myeloma.